TapImmune Inc. Receives Notice of Allowance for U.S. Patent Application Relating to Vaccines Containing TAP for the Treatment of Pox Virus Infections

SEATTLE, April 7, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application number 20100303894 entitled "POXVIRIDAE TREATMENT". This patent claims a vaccine composition containing TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or as an adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.

Back to news